首个口服PCSK9抑制剂Lipfendra:无需注射的高胆固醇治疗新选择
New review of the first oral PCSK9 drug, a needle-free option for high cholesterol
Lipfendra (enlicitide) 获批用于降低高胆固醇,每日一次,无需注射,效果与注射型PCSK9抑制剂相当,价格更亲民。
介绍了首个口服PCSK9抑制剂的临床效果和使用方法,为高胆固醇患者提供了新选择。
A new review from Binghamton University School of Pharmacy and Pharmaceutical Science explores how Lipfendra (enlicitide) can be beneficial for those who have intolerances to injectable medications. The review was recently published in Annals of Pharmacotherapy and was authored by clinical assistant professors Taylor Clark, Rachel Lucas and Mia Lussier, as well as assistant professor Azadeh Nasuhidehnavi.
The FDA's recent approval of enlicitide marks a significant advancement in cholesterol management. This once-daily pill is the first in the PCSK9 inhibitor class, which was previously limited to injectable forms.
Enlicitide effectively reduces LDL ("bad") cholesterol by approximately 57% to 65% in patients already on statins, matching the efficacy of injectable PCSK9 inhibitors. In comparative trials, it lowered LDL by about 65%, outperforming bempedoic acid (6%) and ezetimibe (28%).
Side effects are minimal, with diarrhea and dizziness occurring slightly more often than with a placebo. The recommended regimen involves taking the pill first thing in the morning on an empty stomach, followed by a 30-minute wait before consuming anything other than water, black coffee or plain tea. Enlicitide also serves as a cost-effective alternative to other injectable therapies, priced at $315 for a 30-day supply.
While enlicitide has not yet demonstrated a reduction in heart attacks or stroke, it provides a valuable option for patients who prefer oral medication or require additional LDL lowering beyond what other pills offer.
Publication details
Rachel C. Lucas et al., Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol, Annals of Pharmacotherapy (2026). DOI: 10.1177/10600280261494015
Journal information: Annals of Pharmacotherapy
Key medical concepts
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: New review of the first oral PCSK9 drug, a needle-free option for high cholesterol (2026, November 11) retrieved 11 November 2026 from https://medicalxpress.com/news/2026-11-oral-pcsk9-drug-needle-free.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com